Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.089
Buy
RSI(14)
50.775
Neutral
STOCH(KDJ)(9,3,3)
19.911
Sell
ATR(14)
0.294
High Vlolatility
CCI(14)
9.146
Neutral
Williams %R
75.829
Sell
TRIX(12,20)
0.686
Sell
StochRSI(14)
0.000
Oversold
Search
Traws Pharma Inc
TRAWAdd to Watchlist
1.760USD
+0.130+7.98%
Market hours （ET）Quotes delayed by 15 min
15.96MMarket Cap
2.11P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Traws Pharma Inc
Currency: USD Updated: 2026-05-14Key Insights
Traws Pharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 97 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 5.50.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Traws Pharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Traws Pharma Inc Highlights
StrengthsRisks
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1134.51% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.79M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 1.95, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.52M shares, increasing 23.92% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 5.74.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
5.500
Target Price
+219.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-14The current financial score of Traws Pharma Inc is 8.03, ranking 51 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 106.59%.
Score
Financials
9.74
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
2.86
Growth Potential
10.00
Shareholder Returns
7.58
Traws Pharma Inc's Company Valuation
Currency: USD Updated: 2026-05-14The current valuation score of Traws Pharma Inc is 7.19, ranking 146 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is 1.95, which is 33.74% below the recent high of 2.61 and 180.14% above the recent low of -1.57.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 97/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-14The current earnings forecast score of Traws Pharma Inc is 9.00, ranking 18 out of 382 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 8.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
5.500
Target Price
+219.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Traws Pharma Inc
TRAW
2
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Beigene Ltd
ONC
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-14The current price momentum score of Traws Pharma Inc is 6.74, ranking 192 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.88 and the support level at 0.73, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.846
Sell
MA10
1.721
Buy
MA20
1.494
Buy
MA50
1.672
Buy
MA100
1.709
Buy
MA200
1.884
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-14The current institutional shareholding score of Traws Pharma Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 25.89%, representing a quarter-over-quarter increase of 8.72%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-14The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Traws Pharma Inc is 1.34, ranking 310 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.49. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.49
VaR
+8.49%
240-Day Maximum Drawdown
+65.18%
240-Day Volatility
+148.25%
Return
Best Daily Return
60 days
+28.24%
120 days
+28.24%
5 years
+151.11%
Worst Daily Return
60 days
-22.64%
120 days
-36.36%
5 years
-37.19%
Sharpe Ratio
60 days
+0.02
120 days
+0.32
5 years
-0.27
Risk Assessment
Maximum Drawdown
240 days
+65.18%
3 years
+96.31%
5 years
+99.31%
Return-to-Drawdown Ratio
240 days
+0.23
3 years
-0.33
5 years
-0.20
Skewness
240 days
+0.51
3 years
+7.91
5 years
+7.27
Volatility
Realised Volatility
240 days
+148.25%
5 years
+125.69%
Standardised True Range
240 days
+13.08%
5 years
+106.41%
Downside Risk-Adjusted Return
120 days
+46.20%
240 days
+46.20%
Maximum Daily Upside Volatility
60 days
+145.14%
Maximum Daily Downside Volatility
60 days
+103.35%
Liquidity
Average Turnover Rate
60 days
+31.53%
120 days
+18.23%
5 years
--
Turnover Deviation
20 days
+573.61%
60 days
+138.03%
120 days
+37.65%
Peer Comparison
Biotechnology & Medical Research
Traws Pharma Inc
TRAW
6.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
